The Next Generation Of Metabolic Peptides For Perimenopause And Menopause. What The Research Shows, What The Risks Are, And How One Editor Spent Six Months Finding Out
Most women in perimenopause are handed two options. Wait it out, or take HRT. Both are valid. Neither addresses the metabolic part of the transition that quietly takes apart your sleep, your body composition, your energy, and your ability to think straight while everyone around you keeps asking why you seem tired all the time.
The metabolic part is the part nobody talks about properly. Insulin resistance creeping in. Visceral fat redistributing around the middle for no reason that diet or training will fix. Hot flushes hijacking the night every two hours. The constant low grade exhaustion of a body that no longer responds to the inputs that used to work.
And then a new class of medicine arrives that turns out to address exactly that biology. The GLP-1 family started with semaglutide and tirzepatide. The next molecule, retatrutide, is a triple agonist that adds glucagon receptor activation to GLP-1 and GIP. Alongside it, a separate category entirely, mitochondrial peptides like MOTS-c, encoded inside mitochondrial DNA itself, addressing the energy production decline that drives so much of the perimenopausal experience.
This article is an investigation. What the research actually shows. What the unknowns are. What supervised access in Australia looks like. What the risks are when this category gets pulled into unsupervised gym culture by people who should know better. And one editor's six month case study, supervised by an Australian clinic, with bloodwork and a hormonal foundation in place first, on what happened when this protocol was applied to a perimenopausal body.
Nothing in this article is medical advice. Nothing in this article is a recommendation. Read it as the closest thing to honest editorial reporting on a category that is genuinely changing midlife medicine, and that the wellness industry around it is in some cases handling appallingly badly.
Why Perimenopause Is A Metabolic Event, Not Just A Hormonal One
Oestrogen does more than the textbook gives it credit for, and most of what it does only becomes obvious once it starts to leave. Beyond reproductive function and the things you read about on standard menopause websites, oestrogen is metabolically protective in ways that quietly hold the rest of the body together.
It supports insulin sensitivity, so when oestrogen drops, insulin resistance rises, and that is endocrinology rather than lifestyle. It helps regulate visceral fat distribution, so when oestrogen falls, fat stops sitting on the hips and thighs and starts collecting around the abdomen, where it is metabolically more dangerous and harder to shift no matter how much you train. It supports mitochondrial function, so the energy producing machinery inside every cell of the body becomes less efficient as oestrogen falls, which is part of why the fatigue of perimenopause is not the kind of tired you can sleep off. And it supports thermoregulation in the hypothalamus, which means the narrow band of body temperature the brain considers comfortable narrows further when oestrogen is unstable, which is why hot flushes start getting triggered by smaller and smaller stimuli, sometimes by a single thought.
Underneath all of this, the actual hormone shifting first is not oestrogen at all. It is progesterone, which falls earlier because it is tied to ovulation, sometimes years before menopause is on the radar, and the ratio breaks before the levels do. That broken ratio is what drives the 3am wake-ups, the out of nowhere anxiety, and the body composition shifts that no longer respond to diet or training.
This is the demographic that has been underserved for decades. The standard of care has been HRT for the women who can take it, lifestyle advice for the women who cannot, and a shrug for the women in the middle, with the metabolic dimension of the transition treated as an inconvenience rather than the actual driver. Which is why the GLP-1 class and the mitochondrial peptide class becoming clinically available, even through supervised research and access pathways, is genuinely significant.
What The Research Actually Shows On GLP-1s And Menopausal Symptoms
A 2026 scoping review published in Cureus by Graczyk and Bisschops at Herbert Wertheim College of Medicine summarised what the current literature says about GLP-1 receptor agonists in menopausal and postmenopausal women. The conclusion: GLP-1RAs are associated with increased weight loss and a decrease in central adiposity in this population. A limited number of studies also reported improved vasomotor symptoms and cardiovascular markers, with the caveat that further research is needed before strong clinical statements can be made.
The proposed mechanisms for vasomotor symptom improvement run on three tracks. GLP-1 receptors are present in the hypothalamus, the brain region responsible for thermoregulation, and direct neuronal effects on temperature regulation are an active area of research. Improved insulin sensitivity reduces glucose variability, and glucose fluctuations are a known trigger for hot flushes in women with insulin resistance. And weight loss itself, which GLP-1s reliably produce, has long been associated with reduced hot flush severity independent of any other mechanism.
RAND Corporation published a commentary in August 2025 that summed up the position fairly: GLP-1s appear equally effective for weight loss in postmenopausal and premenopausal women, with limited evidence of enhanced benefit when combined with hormone therapy. The impacts on vasomotor symptoms, bone health and body composition are real but the long term picture remains under investigation.
Read that carefully. The research is encouraging. The research is not yet definitive. Both things can be true.
Retatrutide. The Triple Agonist Producing The Largest Weight Loss Numbers In Pharmacology
Retatrutide is an investigational once-weekly subcutaneous injection developed by Eli Lilly. It is a single molecule that activates three receptors simultaneously: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon. The triple receptor activity is what separates it from semaglutide (GLP-1 only) and tirzepatide (GLP-1 plus GIP).
The phase 2 trial published in the New England Journal of Medicine in 2023 showed up to 24% mean weight loss at 48 weeks. The phase 3 TRIUMPH-4 trial, results announced by Eli Lilly in December 2025, showed mean weight loss of 28.7% at 68 weeks at the highest dose of 12mg in adults with obesity or overweight and knee osteoarthritis. That is the highest mean weight loss number in the history of obesity pharmacotherapy.
Beyond weight, the phase 2 data showed an 82% reduction in hepatic steatosis (fatty liver), significant improvements in HbA1c, fasting glucose, insulin, blood pressure and lipids, and waist circumference reductions of up to 19.6cm. In one analysis 72% of participants on retatrutide who started with prediabetes returned to normoglycaemia by week 48. The placebo group: 22%.
The 2025 review in Diabetes & Metabolic Syndrome described retatrutide as having "the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors."
What it has not yet been formally studied for: vasomotor symptoms, perimenopause specifically, or any indication outside obesity, type 2 diabetes, knee osteoarthritis, MASH (metabolic dysfunction associated steatohepatitis), and cardiovascular outcomes. Seven additional phase 3 readouts are expected in 2026. Eli Lilly is targeting first regulatory submission in 2027 and TGA approval projected for 2027 to 2028.
Until then, retatrutide is an investigational compound. In Australia it is not TGA approved. Access exists for individual patients through specific prescriber-led pathways but it sits outside standard pharmacy supply.
MOTS-c. The Mitochondrial Peptide That Specifically Addresses The Menopause Picture
This is the part of the article that almost nobody has written properly, and it is the part that matters most for women in perimenopause and menopause.
MOTS-c (Mitochondrial Open Reading frame of the Twelve S rRNA-c) is a 16 amino acid peptide encoded inside mitochondrial DNA itself. It was discovered in 2015 by Dr Changhan Lee and colleagues at the University of Southern California Davis School of Gerontology, in a paper published in Cell Metabolism. The discovery was significant because it changed the textbook understanding of mitochondria from organelles that produce energy into organelles that also produce signalling peptides that regulate metabolism across the entire body.
What makes MOTS-c clinically interesting for perimenopausal women is documented in animal research that maps almost exactly onto the metabolic experience of menopause.
A 2019 study published in Aging showed that MOTS-c treatment in mice prevented ovariectomy-induced obesity and insulin resistance. Ovariectomy is the experimental model researchers use to mimic surgical menopause. After ovariectomy, low oestrogen levels increased fat mass overload and disturbed normal adipose function, forcing the development of insulin resistance. MOTS-c treatment increased brown fat activation, reduced fat accumulation, lowered inflammatory markers including IL-1β and IL-6 in adipose tissue, and activated the AMPK pathway to improve energy dissipation and insulin sensitivity.
A 2019 review titled MOTS-c: an equal opportunity insulin sensitizer summarised the position: MOTS-c reduced both the weight gain and the insulin resistance associated with experimental menopause. Plasma MOTS-c levels also decline with age. Levels in skeletal muscle and plasma of aged mice are lower than younger mice, and systemic injection of MOTS-c in aged mice can restore those levels and reverse age-related skeletal muscle insulin resistance.
A 2026 review in Peptide Sciences on MOTS-c and nuclear gene regulation in aging research observed that exogenous MOTS-c is capable of preventing diet, aging and menopause associated metabolic dysfunction and insulin resistance, but has limited impact on the resting metabolism of healthy young mice. In other words, MOTS-c works by addressing dysregulation. If the system is functioning, the effect is small. If the system is broken, the effect is significant.
That is the mechanism. Women in perimenopause and menopause are the population in which the relevant biology is most dysregulated. The mechanistic logic for why MOTS-c would help midlife women specifically is genuinely compelling. The clinical trial data in human women is where the gap remains. Most published research is animal model based, with human studies still emerging.
So what we have is a biologically plausible therapy with strong preclinical data, accessed in supervised settings by women in midlife, with reported clinical benefit ahead of where the formal regulatory approval pathway sits. That is exactly where new medicine usually begins.
An Editor's Note. What Six Months Of Supervised Treatment Actually Looked Like
Editor's note from Lisa:
''I'm sharing this story in the hopes that it helps a lot of women out there. I know it is a lot to take in, but it is worth the read.
The abstract science only goes so far, so this is the part of the article where I tell you what happened to me, including the bloodwork, the imaging and the protocol that finally moved the needle after five years of menopause and six months of relentless hot flushes that nothing in my existing toolkit could touch.
I am 54 and have been in menopause since I was 49, which means I have been doing this for five years. The hot flushes have always been there, usually one to two hours apart around the clock, normally on for three months and then off for three months in some kind of strange internal weather system that I had learned to live around. The exception has been the last six months, when something shifted and the loop simply did not break, and I found myself stuck in a relentless cycle that nothing in my existing toolkit could touch. The sleep deprivation was the hardest part of it, because trying to work and run meetings while your face turns blood red and you are visibly on fire mid-sentence becomes its own ongoing professional problem on top of the physical one. I had been waking every two hours through the night, drenched, then trying to get back to sleep before the next one hit, with the fan on my bedside table running constantly and a portable fan in my handbag for whatever room I happened to be in. I had not had an unbroken night's sleep in six months, my energy was gone, my body composition had shifted in ways that no amount of training was changing, and I had tried every supplement stack I could find along with oestradiol patches and progesterone capsules without anything actually moving the needle.
So I went back to first principles and ran the bloodwork properly across two panels several months apart. The results came back with several genuine red flags that nobody had previously caught. I am sharing the full breakdown here because if you are sitting in midlife wondering what to ask your doctor for, this list is a starting point for the conversation. Most of these markers are not on standard panels, and a lot of women only find out they were never tested when something tips over so feel free to pass them onto your doctor.
The red flags:
-
- Lipoprotein(a) at 221 nmol/L. High cardiovascular risk band per Australian Atherosclerosis Society guidance. Sits in the 95th to 99th percentile of the population. Genetically inherited, not modifiable by diet or exercise, and not on standard cholesterol panels.
- LDL cholesterol elevated at 5.2 mmol/L (range 1.5 to 3.4). Stable across both panels, so not climbing, but well above target.
- Apolipoprotein B at 1.4 g/L. The lab flags anything from 1.0 g/L upward as increased cardiovascular risk. ApoB counts the actual atherogenic particles, often a more accurate cardiovascular marker than LDL alone.
- Familial hypercholesterolaemia flagged by the lab. An inherited autosomal dominant condition that affects how the body clears cholesterol. My father has it. The lab calculated my diagnostic likelihood at approximately 1 in 5.
- Total testosterone at 0.4 nmol/L. Bottom of the reference range (0.4 to 1.4).
- Sex Hormone Binding Globulin elevated at 134 nmol/L (range 20 to 118). High SHBG binds testosterone and reduces what is biologically available, so the picture overall was very low free androgen activity, which lines up with the energy and muscle responsiveness symptoms I've been experiencing.
- Transferrin slightly low at 31 µmol/L (range 32 to 48). Same on both panels.
- Neutrophils trending down. 1.8 in December, 1.4 in March (range 2.0 to 7.5). Lab flagged neutropenia, with viral infection or medication noted as common causes.
- Homocysteine trending up. 7.1 in December, 8.4 in March. Both within range (4 to 14) but the direction matters as an independent cardiovascular risk factor.
What was clean:
-
- Fasting insulin at 3 mU/L. Normal insulin sensitivity range, was not previously and had taken a lot of work to get this to a normal level through food.
- HbA1c at 5.4% and fasting glucose 5.3 mmol/L. Both well within healthy.
- Liver enzymes all clean (ALT, AST, GGT all within range, slightly improved across the two panels).
- Kidney function normal with eGFR over 90.
- Vitamin D sufficient at 78 nmol/L.
- Active B12 and folate both well into the sufficient range.
- TSH at 1.2 to 1.3 with no autoimmune thyroid antibodies. Excellent thyroid function.
- Ferritin at 125. Comfortable iron stores.
- FSH at 121, LH at 27.8, oestradiol at 135 pmol/L, progesterone undetectable. A textbook postmenopausal hormone profile, lining up with five years on the other side of my last period.
So the picture was a woman whose metabolic engine was running fine, whose hormonal foundation was depleted, and who carried a genetic cardiovascular risk profile inherited from her father that nobody had previously flagged because the relevant markers had not been on standard panels. None of this was fine. All of it was workable with the right team and the right sequencing.
The right response to the cardiovascular flags was imaging. So I had a CT coronary angiogram and calcium score scan to find out what the genetic risk was actually doing to my arteries, because numbers on paper only tell you so much and the question that mattered was whether the disease had started building.
The imaging results:
-
- Coronary calcium score: zero. The lowest possible percentile rank for my age and sex according to the MESA cohort.
- Left main coronary artery: appears normal.
- Left anterior descending artery (LAD): appears normal.
- Circumflex artery: appears normal.
- Right coronary artery: appears normal.
- Conclusion: "The epicardial coronary arteries appear normal by CT angiography. There are no additional cardiac findings of relevance within the scanned segments."
That result reframed the whole picture. I have inherited the genotype for higher cardiovascular risk, but the imaging confirmed I do not currently have the phenotype, the actual disease building in my arteries. That is the difference between a flag on bloodwork and an active problem, and it is exactly why imaging matters when bloodwork raises questions. The cardiovascular conversation now is about prevention with the right team rather than treatment of something already there, and that conversation continues alongside everything else.
From there I worked with a doctor and a clinic that took the full picture seriously and built the protocol from the foundation up, with the hormonal layer going in first and everything else sequenced after the foundation was in place. Then came the metabolic layer, retatrutide and MOTS-c supervised by the clinic with regular bloodwork and dose protocols. Both peptides are accessed in Australia through specific prescriber-led pathways, and I am not going to publish a how-to here because that would fall outside TGA compliance and is not the point of this article anyway. The point is what happened.
The hot flushes stopped. Not faded. Stopped. Within a few days I was sleeping through the night for the first time in six months, the exhaustion lifted, my waist measurement which had been climbing for two years no matter what I did started moving in the other direction, energy returned, and the constant low-grade fog that had become my baseline cleared.
I am not the population of a randomised controlled trial. I am one woman, supervised, with the right bloodwork and the right sequencing, and what I can tell you is that for me, in the right context, this protocol did what nothing else had done. The genetic cardiovascular markers, the low free androgen activity, the neutropenia trend and the other watch-list items continue to be tracked alongside the metabolic markers, because supervision is not a one-time event, it is an ongoing relationship with a clinical team who is watching all of it. The peptides are addressing one layer. The other layers still need their own conversations.
It does suppress your appetite, and that is the part where you have to be deliberate, so I make sure I still eat, with protein in particular because muscle loss is one of the documented risks if you do not protect against it, and I train with weights, which every woman in midlife should be doing anyway for the reasons explained further down this article. The drug is a tool. The lifestyle is what makes the tool work.
What I can also tell you is that this is not a substitute for the rest of the picture. Hormonal foundation matters, bloodwork matters, supervision matters, imaging matters when the bloodwork raises questions, and lifestyle matters across protein, resistance training, sleep and nervous system regulation. None of that goes away because you have added a peptide layer. The peptides sit on top of all of that, not instead of it.''
The TIDES Health Sequencing Framework
This article would not exist without TIDES Health, the Australian pharmacist-led clinic that has been one of the few practices framing midlife metabolic medicine as a multi-system event rather than a single hormone or single drug to try. Their position on sequencing is the editorial spine of this piece.
From TIDES Health:
''Perimenopause is not just low oestrogen. It is a hormonal storm. Progesterone drops first, often years before menopause is mentioned, because it is tied to ovulation. Oestrogen does not gently decline; it spikes erratically and crashes, sometimes higher than it ever was in your twenties. That broken ratio is what drives the 3am wake-ups, the out of nowhere anxiety, and the body composition shifts that no longer respond to diet or training.
Hormones first. Everything else is a layer. Peptides and GLP-1s are not a substitute for hormone replacement therapy, they are a layer that sits on top. The first conversation in perimenopause should almost always be about progesterone, the hormone that is actually deficient, because adding oestrogen too early while your ovaries are still firing unpredictably can make symptoms worse. An AMH blood test tells you where you stand, and when AMH is essentially undetectable and you have gone twelve months without a period, that is clinical menopause and the point at which oestrogen replacement enters the picture. Get this sequence right, and everything else works dramatically better.
Where GLP-1s genuinely earn their place. Once the hormonal foundation is set, GLP-1 receptor agonists become one of the most useful tools for the metabolic side of the transition. The shift from your late thirties is not just a few extra kilos, it is insulin resistance creeping in, visceral fat redistribution, and the food noise that was not there before. GLP-1s address all three. They are not magic and they are not for everyone, but for the right woman at the right stage, they quiet the noise and make lifestyle inputs work again.
The second layer covers sleep, recovery, and growth hormone. Beyond metabolism, targeted peptide therapy can support sleep architecture, anxiety regulation, and the growth hormone axis for recovery, body composition and skin quality. One clinical nuance most people miss: IGF-1 production at the pituitary is partially oestrogen-dependent, meaning these peptides work meaningfully better once oestrogen is stable. This is exactly why we sequence the way we do. Hormones first. Metabolic support next. Peptides last. Out of order, you will spend a lot of money chasing symptoms instead of resolving them.'' — Emil Demyane, Director, Tides Health
Book a consultation with TIDES Health
The full TIDES Health contributor section sits at the end of this article.
The Bloodwork Schedule. What Should Actually Be Tested And How Often
If a prescriber puts you on any GLP-1 class or peptide protocol without baseline bloodwork and an ongoing schedule, find a different prescriber. This is not optional.
Before starting (baseline panel, all markers in a single blood draw):
- HbA1c (glycated haemoglobin, three month average blood glucose)
- Fasting glucose and fasting insulin
- HOMA-IR (calculated from fasting glucose and insulin, the standard insulin resistance measure)
- Comprehensive metabolic panel: ALT, AST, GGT (liver), creatinine and eGFR (kidney), full electrolyte panel
- Lipid panel: total cholesterol, LDL, HDL, triglycerides
- TSH, free T3, free T4 (thyroid function)
- Lipase and amylase (pancreatic enzymes)
- Female hormone panel: oestradiol, progesterone, FSH, LH, AMH, testosterone, SHBG, DHEA-S
- Vitamin D, B12, ferritin, iron studies
- FIB-4 score and full liver function if any liver involvement is suspected
- For anyone at musculoskeletal risk: baseline DXA scan to track bone density and body composition
At 6 to 8 weeks:
- ALT, AST, GGT
- Creatinine and eGFR
- Fasting glucose and HbA1c
- Lipase if any abdominal symptoms
- Symptom review with prescriber
Every 3 to 6 months thereafter:
- HbA1c and fasting glucose
- Liver enzymes (often improve on these protocols, monitoring confirms direction)
- eGFR and kidney function
- Lipid panel
- TSH (weight loss alters thyroid hormone requirements; weight loss often means thyroid medication needs adjustment)
- Body composition assessment if available, ideally DXA. Fat mass versus lean mass tells you what the protocol is actually doing in a way the scale never will
- Hormone panel reviewed in context of the broader protocol, particularly if HRT is also in play
If symptoms develop:
Persistent abdominal pain warrants urgent lipase and amylase testing to rule out pancreatitis. Acute pancreatitis is a rare but serious adverse event in the GLP-1 class. Persistent vomiting requires hydration assessment and electrolyte review. Severe headache, vision changes, or chest pain warrants immediate medical review.
Side Effects. The Full Picture, Both Directions
What people commonly report on the positive side:
- Reduced appetite and improved satiety
- Reduction in food noise (the constant intrusive thinking about food that disappears for many users)
- Sustained weight reduction with central adiposity preferentially shifting
- Improved insulin sensitivity and glucose stability
- Reduced hot flush frequency and severity in some women, mechanism still under investigation
- Improved sleep quality, partly downstream from vasomotor symptom improvement
- Reduced cravings for alcohol and other reward-driven behaviours, currently the subject of clinical trials investigating GLP-1 use in alcohol use disorder
- Improved mood and mental clarity in some users, downstream of better metabolic stability
- Increased energy, particularly relevant in the MOTS-c picture given its mitochondrial mechanism
Common gastrointestinal side effects (well documented in the GLP-1 class):
- Nausea, particularly in the first one to two weeks at each new dose level. Affects up to 60% of users at higher doses
- Vomiting, diarrhoea, constipation, abdominal discomfort
- Reflux and increased burping due to slowed gastric emptying
- Reduced bowel motility leading to slower transit times
Less common but documented:
- Dysesthesia (altered skin sensation), reported in approximately 21% of retatrutide users in trial data
- Heart rate increases of 5 to 10 beats per minute on retatrutide, peaking around week 24 and declining toward baseline by weeks 36 to 48
- Transient elevations in liver enzymes (ALT) in approximately 1% of users
- Hair loss, generally weight-loss-related rather than drug-specific
- Injection site reactions
Rare but serious adverse events:
- Acute pancreatitis. Reported in approximately 0.4% of phase 2 retatrutide participants. Class warning across all GLP-1 receptor agonists. Persistent severe abdominal pain requires urgent assessment
- Gallbladder disease including gallstones. Affects approximately 1.1% of retatrutide users in trial data. Rapid weight loss is an independent risk factor for gallstones, not unique to this drug class
- Acute kidney injury, typically secondary to dehydration from gastrointestinal side effects. Rare but documented
- Hypoglycaemia, particularly when used alongside insulin or sulfonylureas in diabetic patients
- The TGA updated safety information across the GLP-1 class in mid-2025 to include warnings about potential psychological effects, including the risk of suicidal thoughts or behaviours. Class-level regulatory monitoring, not a proven causal link
The unknowns:
- Long-term safety beyond five years remains under investigation across the entire GLP-1 class
- Lean muscle mass loss. Studies suggest 25 to 40% of total weight loss on semaglutide can be lean mass rather than fat. Inadequate protein intake and absence of resistance training make this worse
- Bone mineral density. A 2024 phase 2 randomised controlled trial found 52 weeks of weekly semaglutide reduced hip BMD by 2.6% and lumbar spine BMD by 2.1% compared to placebo. For postmenopausal women already at fracture risk, this is not trivial
- Thyroid C-cell tumour signal in rodents at clinically relevant exposures. No proven causal link in humans but follow-up data is not yet long enough to close the question. People with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not take these drugs. Hard contraindication
- Pregnancy outcomes. Limited human data, animal data raises legitimate concern, manufacturer guidance is washout before conception
What To Eat. The Reality Of Nutrition On A GLP-1 Class Protocol
Standard nutritional advice on these medications is "eat more protein." That advice ignores the lived experience of being on the drug, which is that appetite is genuinely suppressed and many users struggle to eat anything at all, let alone enough to protect lean muscle.
For perimenopausal and menopausal women, the muscle question is more urgent than for any other demographic. Sarcopenia, the age-related loss of muscle mass and strength, accelerates after menopause. Resistance training and adequate protein intake are the only proven interventions. Adding a drug that suppresses appetite into that picture, without a strategy, makes the underlying problem worse.
What clinicians who actually work with this population recommend:
- Protein first at every meal. Eggs, Greek yoghurt, fish, chicken, tofu, lean red meat. Eat the protein before anything else on the plate, while the appetite is still functional
- Protein at breakfast specifically. Most women under-eat protein at breakfast. On a GLP-1 protocol that gap compounds because by lunch the appetite is suppressed further
- On hard days, use protein shakes or bone broth. Whey, casein, or plant-based protein powders. Bone broth for collagen and easier digestion. These are not replacements for whole food but they protect intake on the days food feels impossible
- Resistance training two to three times a week minimum. Compound movements. Squats, deadlifts, presses, rows. Heavy enough to challenge. Bodyweight is fine if equipment access is limited but progressive load matters
- Hydration with electrolytes. Sodium, potassium, magnesium. GI side effects can drive dehydration fast and that creates kidney stress as well as making the side effects feel worse
- Adequate fibre, slowly introduced. Slowed gastric emptying plus high fibre too quickly equals abdominal discomfort. Build it in gradually
- Track body composition, not scale weight. A DXA scan every six to twelve months tells you what is actually being lost. Scale weight will mislead
- Vitamin D, B12 and iron levels reviewed regularly. Reduced food intake makes deficiencies more likely
For perimenopausal women specifically, the protein target most often cited is 1.6 to 2.2 grams per kilogram of body weight per day, distributed across meals. Hitting this on an appetite-suppressing protocol is genuinely difficult and requires planning, not willpower.
The Pregnancy Question. Why Retatrutide Has A Longer Washout Than Semaglutide
This section is for any woman of reproductive age considering a GLP-1 class protocol, and it is non-negotiable.
Semaglutide has a half-life of approximately one week, and the manufacturer-recommended washout before conception is two months. Retatrutide has a half-life of approximately six to eight days, which is similar to semaglutide on paper but with greater receptor accumulation due to triple agonism, and pharmacokinetic data suggests meaningful plasma levels persist for several weeks after the final dose. The conservative washout estimate sits at eight to ten weeks minimum, with some clinicians advising twelve weeks.
Animal data raises legitimate concern across the entire GLP-1 class. Pregnant rats, rabbits and cynomolgus monkeys given semaglutide showed embryofetal mortality, structural abnormalities, early pregnancy losses and altered foetal growth, and many of these findings occurred alongside marked maternal weight loss and reduced food intake, which complicates interpretation but does not change the precautionary principle. The Australian TGA classifies semaglutide as Category D for pregnancy, meaning there is evidence of human foetal risk, while retatrutide does not yet have a TGA pregnancy category because it is not yet TGA approved.
The fertility paradox is real and rarely discussed. For women with PCOS or insulin resistance, GLP-1 protocols can restore ovulation and regular cycles, and women who believed they were not fertile have become pregnant unexpectedly. If you are on a GLP-1 protocol and do not wish to conceive, reliable contraception is not optional. If you do wish to conceive, the planning window must account for the full washout before actively trying.
If pregnancy is discovered while on any GLP-1 protocol, stop the medication immediately and contact your prescriber.
The Megadose Problem. Why The Gym Generation Is Getting This Catastrophically Wrong
This is the part of the article that exists as public service, because the unsupervised use of these compounds in gym culture is producing real harm and almost no mainstream coverage is talking about it honestly.
Retatrutide in trial conditions is administered at 4mg, 9mg and 12mg weekly with strict dose escalation protocols, and the 12mg dose was the highest tested in TRIUMPH-4, producing the 28.7% mean weight loss alongside the highest incidence of gastrointestinal adverse events. About 12 to 18% of trial participants discontinued due to side effects, which gives you a sense of how the supervised version of this drug actually behaves at its top end.
The problem is human nature. People watch the scale move and assume that if some is working, more will work better, so they see the weight come off in the first month and double the dose to accelerate it, skip the titration schedule because they feel fine, and run two compounds at once because they read on Reddit that stacking gets faster results. This is where the liver becomes the silent casualty.
The Liver Mechanism Nobody Explains
GLP-1 class compounds work in part by accelerating the mobilisation of stored fat. Triglycerides are released from adipose tissue and processed through the liver. In a healthy liver this is fine. In a liver already carrying fatty deposits, already running elevated GGT, already showing an unhealthy triglyceride to HDL ratio, this acceleration magnifies the existing problem rather than resolving it.
Higher doses run this process faster. The liver works harder. Lipolysis exceeds the liver's processing capacity. Liver enzymes spike. In the worst cases, what looked like dramatic weight loss is also early-stage drug-induced liver injury that nobody noticed because nobody was checking.
Non-alcoholic fatty liver disease, now reclassified as MASLD, affects roughly one in three Australian adults. Many have no symptoms and no diagnosis. The liver carries the load quietly until something pushes it. A megadose protocol is exactly the kind of push that surfaces the dysfunction in the most damaging way.
This is also why baseline liver assessment matters before starting any GLP-1 class compound. GGT, TG to HDL ratio, ferritin, ALT and AST tell a prescriber what the liver is doing now. Without those numbers, the dose escalation conversation is happening blind.
What's Actually Being Seen In Unsupervised Use
- Doses well above 12mg weekly, sometimes 15 to 20mg, in pursuit of faster fat loss
- Twice-weekly or more frequent dosing intervals, ignoring the 6 to 8 day half-life and stacking effects on top of unprocessed earlier doses
- Concurrent use with anabolic steroids, growth hormone, or other peptides without bloodwork or medical supervision
- Compounds purchased from unregulated sources with no certificate of analysis, no sterility testing, and unknown actual potency. The FDA has documented heavy metals, endotoxins and incorrect peptide sequences in unregulated GLP-1 peptide samples
- No baseline bloodwork, no monitoring schedule, no exit strategy
- Continued dose escalation in users already losing weight, on the assumption that more dose equals more results
The Downstream Consequences Documented In Case Reports And Clinical Observation
- Acute pancreatitis at higher rates than seen in supervised trial populations
- Liver enzyme spikes and drug-induced hepatotoxicity, particularly in users with undiagnosed pre-existing fatty liver. The mechanism is exactly the lipolysis overload described above
- Severe muscle loss in young men running these compounds without resistance training or protein intake
- Cardiac strain from sustained heart rate elevation, particularly when stacked with stimulants or anabolics
- Severe dehydration and acute kidney injury from unmanaged GI side effects
- Mental health deterioration, including the suicidal ideation signal flagged by the TGA, more pronounced in unsupervised users without screening
- Eating disorder relapse or new development in young women using these compounds for cosmetic weight loss
- Hypoglycaemic episodes in users who do not understand the metabolic shifts the drug produces
- Gallbladder events from rapid weight loss, magnified by faster lipolysis at higher doses
The Psychology Of "If It's Working, More Must Be Better"
This is the part nobody is willing to say out loud. People are not stupid, but they are predictable. Watching the scale drop creates a positive feedback loop that overrides the original protocol agreement. The first month feels miraculous. The second month feels slower. The temptation to push the dose to recreate the first-month effect is universal, and it is exactly the wrong response.
The plateau is not a sign that the dose is too low. The plateau is the body adjusting. Pushing through it with more drug accelerates every adverse outcome listed above without producing proportionally more fat loss. The TRIUMPH trial data shows clear diminishing returns above 12mg weekly. The risks do not diminish. They scale.
This is why supervised access matters. A clinician with bloodwork in front of them every six to eight weeks sees the liver enzymes start to climb before the user feels anything. A user looking at the scale sees only the number going down and reaches for the next vial.
The Regulatory Picture
The TGA has issued explicit warnings about unapproved peptide products, naming retatrutide directly, and is actively pursuing prosecution of suppliers operating outside the regulatory framework. The Australian Border Force is targeting illegal peptide importations using data-driven intelligence. The FDA in the United States issued more than 50 warning letters to GLP-1 compounders in September 2025 alone.
If you are seeing retatrutide or MOTS-c sold online with "research use only" disclaimers, with no prescriber requirement, with no medical supervision, you are looking at the part of the market that is producing the case reports above.
This category will eventually be approved, regulated and accessible through standard pathways. Until then, it requires medical supervision. Not Reddit. Not gym chat. Not a drop-shipped vial from an offshore supplier. And not the assumption that if some is working, more will work better. That assumption is what puts people in hospital.
Who This Is Not For
The supervised access conversation is meaningful only when it sits inside the right clinical picture. The supervised pathway is not for everyone, and a responsible clinician will say no in any of the following circumstances:
- Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Hard contraindication
- Personal history of pancreatitis
- Severe gastroparesis or established motility disorders
- Active eating disorder or significant disordered eating history
- Pregnancy or planning pregnancy within the washout window
- Breastfeeding
- Severe psychiatric history requiring careful prescriber review, particularly active depression with suicidal ideation
- Severe renal or hepatic impairment
- Type 1 diabetes (these drugs are not appropriate for type 1)
- Normal BMI without metabolic dysfunction. The risk-benefit calculation changes entirely outside the indicated population
- Inability or unwillingness to commit to ongoing bloodwork and supervision
What Australians Can Currently Access For The Metabolic Layer
For perimenopausal and menopausal women in Australia working with their doctor on the metabolic layer of the transition, the TGA-approved options are:
Wegovy (semaglutide 2.4mg weekly injection). TGA approved for chronic weight management and for cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity. Available at Australian pharmacies on private prescription.
Mounjaro (tirzepatide weekly injection). TGA approved since September 2024 for chronic weight management. More recently approved for moderate to severe obstructive sleep apnoea in adults with obesity. Dual GIP and GLP-1 receptor agonist. Average weight loss in trials around 20 to 21%. Highest weight loss number among TGA-approved options.
Contrave (naltrexone and bupropion). Oral combination tablet. Works on appetite and reward pathways. TGA approved for weight loss since 2019.
Duromine (phentermine). Older stimulant appetite suppressant. Short term use only.
Xenical (orlistat). Fat absorption blocker. Available over the counter at lower dose, prescription at higher dose.
Saxenda (daily liraglutide) was previously TGA approved but Novo Nordisk discontinued it in Australia at the end of 2025. Patients have been transitioned to Wegovy.
None of these are PBS subsidised for weight management. All are private prescription only. Eligibility requires BMI of 30 or above, or 27 or above with a weight-related condition. Speak to your doctor.
For investigational compounds including retatrutide and MOTS-c, supervised access pathways exist for specific patients through specific Australian clinics. The detail of how those pathways operate is a conversation between you, your doctor and the clinic. Not an article.
What Comes Off, Eventually. The Exit Plan
The Wegovy and GLP-1 article on this site already documented what happens when GLP-1 therapy stops. Most people regain a substantial proportion of lost weight within one to two years. The biology that drove the original picture does not disappear because you spent a year on medication.
For women who have done the hormonal foundation work alongside the metabolic layer, the picture is different but not entirely different. Hormone replacement therapy continues to address the hormonal driver. Lifestyle, protein, resistance training, sleep regulation continue to do the heavy lifting. The peptide layer can be tapered, cycled, or maintained at a lower dose depending on the protocol and the prescriber.
The exit plan is part of the protocol from day one, not an afterthought at month twelve. If your prescriber has not discussed what coming off looks like, ask.
The Editorial Bottom Line
The next generation of metabolic peptides is genuinely changing what is possible for women in perimenopause and menopause. The research on retatrutide is the strongest weight loss data in pharmacology. The research on MOTS-c maps almost exactly onto the metabolic experience of menopause. The clinical observations from supervised users line up with what the mechanisms predict.
None of that is a recommendation. None of that is a replacement for a real conversation with a real clinician who knows your history, your bloodwork, your hormonal picture and your life. None of that means buying compounds from offshore suppliers and self-administering. None of that is an excuse to skip the hormonal foundation, skip the bloodwork, skip the protein, skip the resistance training.
What it means is that for the right woman at the right stage of the transition, supervised access to this category of medicine is producing results that the standard menopause toolkit has not produced. That is significant. That deserves coverage. And it deserves to be covered honestly, with the risks named, the unknowns acknowledged, and the unsupervised use of these compounds called out as the public health problem it has become.
If you are a woman in midlife, exhausted, gaining weight you cannot shift, hot flushes hijacking your sleep, energy gone, and you have been told everything is normal while you feel anything but, this article is for you. The medicine exists. The supervised pathway exists. The conversation with the right clinician is the next step.
Not the next gym chat. The next clinician.
How TIDES Health Can Help
The clinical voice through this article is TIDES Health, an Australian pharmacist-led clinic that treats perimenopause and menopause as the multi-system event it actually is. From TIDES:
''At TIDES Health, we treat perimenopause and menopause as the multi-system event they actually are, not a single hormone to top up or a single drug to try. Our pharmacist-led team works alongside experienced prescribers across bioidentical hormone therapy, GLP-1 protocols, compounded peptide therapy, and the bloodwork that holds it all together. If Lisa's story sounds like yours, if you have been told everything's normal while you feel anything but, book a consultation. We will meet you where you are, sequence things properly, and walk the journey with you.'' — Emil Demyane, Director, Tides Health
Sources
Eli Lilly. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. 11 December 2025. investor.lilly.com
Jastreboff AM, et al. Triple Hormone Receptor Agonist Retatrutide for Obesity. A Phase 2 Trial. New England Journal of Medicine, 2023. nejm.org
Hochuli M, Lehmann R. Retatrutide. A Game Changer in Obesity Pharmacotherapy. 2025. PMC12190491
Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. cell.com
Lu H, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. Aging, 2019. PubMed 30725119
Kim KH, et al. MOTS-c. An Equal Opportunity Insulin Sensitizer. 2019. PMC6462348
Graczyk NA, Bisschops J. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause. A Review. Cureus, 16 January 2026. PMC12908505
Therapeutic Goods Administration. Update on the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) pharmacy compounding changes. 23 October 2025. tga.gov.au
Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. 2026.
Therapeutic Goods Administration. GLP-1 RAs warnings aligned over potential risk of suicidal thoughts or behaviours. Mid 2025. tga.gov.au
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). NEJM, 2023.
RAND Corporation. GLP-1 Agonists in Perimenopause. Unique Risks and Potential Opportunities. August 2025. rand.org
Related Reads
A Pill For Weight Loss Was Always Going To Break The Internet
GLP-1 Explained, Wegovy, Ozempic, PCOS, Liver Health And Australian Access
Serena Williams Ozempic Weight Loss Deal
